Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AG-707 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AG-707 | DRUG | - |
Inclusion Criteria: * Patients must be seropositive for HSV-2 (+/- HSV-1) and have a documented history of clinically active genital herpes (at least one prior outbreak). * Patients must be seronegative for HIV. * Patients must be seronegative for hepatitis B and C * Have baseline chemistry and hem...
AG-707 is an investigational small molecule being developed for the treatment of genital herpes. It is intended to address this infectious disease condition, though it remains in clinical development and is not yet approved for commercial use.
AG-707 is being developed by Agenus Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AGEN. The company is conducting clinical research to evaluate the safety and immune response of this investigational drug.
AG-707 is in Phase 1 clinical development. A Phase 1 trial has been completed, which focused on evaluating the safety, tolerability, and immune response of the drug in patients with genital herpes. It remains an investigational agent.
AG-707 has one completed Phase 1 clinical trial registered under NCT00231049. This trial evaluated the safety, tolerability, and immune response of AG-707 in 35 participants with genital herpes in the United States. The trial was not blinded and did not use a control group.
AG-707 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial for genital herpes. Further clinical development and regulatory review would be required before it could be considered for approval.